Investor Overview

Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK."

Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic... 
More >>
ITEK (Common Stock) $7.11 Stock is Up 0.16 (2.30%)08/30/16 4:00 p.m. ET
Recent NewsMore >>
DateTitle 
Aug 24, 2016Inotek Pharmaceuticals Announces the Completion of the Recruitment Phase of MATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma
- Top-line Data Expected in December 2016 - LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 24, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the completion of the active recruitment phase of MATrX-1, the first pivotal Phase 3 trial of trabodenoson for the treatment of glaucoma. Trabodenos... 
Printer Friendly Version
Aug 18, 2016Inotek Pharmaceuticals Appoints Patrick Machado, JD, to Board of Directors
LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 18, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company” or “Inotek”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Patrick Machado, JD, has been appointed to its Board of Directors. Mr. Machado will serve on the Audit Committee. Mr. Machado most recently served as Co-Fo... 
Printer Friendly Version
Aug 10, 2016Inotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial Results and Operational Highlights
-Initiated Phase 2 Study of Fixed-Dose Combination of Trabodenoson and Latanoprost- -Phase 3 MATrX-1 Trial of Trabodenoson in Glaucoma on Track for Completion in 4Q 2016- LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 10, 2016-- Inotek Pharmaceuticals Corporation (the “Company” or “Inotek”), (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular ... 
Printer Friendly Version
Aug 2, 2016Inotek Pharmaceuticals Announces Pricing of $50.0 Million of 5.75% Convertible Senior Notes due 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 2, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (the “Company”) today announced the pricing of an underwritten public offering of $50.0 million aggregate principal amount of 5.75% Convertible Senior Notes due 2021 (the “Notes”). The Company has granted the underwriters a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of Notes. The offering is expected to close on or... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
10/15/16
American Academy of Ophthalmology 2016 Annual Meeting
LocationChicago, IL
Data provided by Nasdaq. Minimum 15 minutes delayed.